Lars Anker, MD

  • Neurosurgery
    (Board Certified)
1310 W. Stewart Dr., Suite 212
Orange, CA 92868
Medical Groups & Affiliations
  • St. Joseph Heritage Medical Group
  • St. Joseph Hospital Affiliated Physicians
Accepting New Patients

Primary Office

1310 W. Stewart Dr., Suite 212
Orange, CA 92868
Get Directions
(714) 450-6880
(714) 450-6801
Mon - Fri: 8 a.m. - 4:30 p.m.

Secondary Office

(714) 734-3120

More Information

  • Meet The Provider

    Specialties & Education

    Primary Specialties
    • Neurosurgery
      (Board Certified)
    Education & Training
    • Medical School
      University of Hamburg- Hamburg, Germany - 1994
    • Fellowship
      University of Southern California- Los Angeles, CA - 1996
    • Internship
      University of Minnesota- Minneapolis, MN - 1997
    • Residency
      University of Minnesota- Minneapolis, MN - 2001
  • Biography



    Dr. Anker is broad certified in Neurological Surgery with a focus in a variety of conditions including disorders of the nervous system, Laminectomy, Glioblastoma, and spinal disc herniation, just to name a few. He is an active member in several societies including American Association of Neurological Suregons, California Association of Neurological Surgeons, and Society of Neuro-Oncology; just to name a few.

    Dr. Anker has the best bedside manner with his patients and their families. He treats all his staff with respect and grace and is a great team leader. He is highly intelligent, driven, yet humble and easily connects with staff and patients. He is a leader that exhibits all the qualities of dignity and excellence. He frequently receives acts of appreciation from his patients, their families and his peers.

    He was the first physician to initiate a complex vaccine study at two St. Joseph Health Ministries with the St. Joseph Health System Cancer Consortium. Dr. Anker also participates in The Cancer Prevention and treatment Biospecimen Repository Protocol in 2010; Phase III Radnomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases also in 2010; Phase II double blinded placebo controlled study of Bevacizumab with or without AMG 386 in patients with recurrent Gliboblastoma or Gliosarcoma in 2013; and Phase III clinical trial evaluating DVC ax@-L, autologus dendtritic cells (DC) pulsed with tumor lysate antigen for the treatment of Glioblastoma Multiforme (GMB) in 2012.

    In 2013, he started Phase I/II Trial of Concurrent RAD001 (Everolimus) with Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma. In 2014, Dr. Ankers also Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221; Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme.

    • Physicians of Excellence, OCMA - 2016
    • Physicians of Excellence, OCMA - 2018